A clinically valuable radioligand for HER2 molecular imaging in breast cancer and gastric cancer would require minimal normal liver and stomach uptake, as well as the ability to bind to HER2 in the presence of concomitant anti-HER2 therapy. Here, ERBB2 is linked to gastric cancer.